- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03471130
Definitive QT Study With MT-8554 (MT-8554 DQT)
May 12, 2023 updated by: Mitsubishi Tanabe Pharma America Inc.
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects
This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF) from Baseline in healthy adult subjects
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
City Name, United Kingdom
- Investigational center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 1. Provide written informed consent to participate in this study.
- 2. Healthy and free from clinically significant illness or disease as determined by medical history, physical examination (PE), laboratory, and other tests at Screening and Admission.
- 3. Male and female subjects, aged 18 to 55 years (inclusive) at Screening.
- 4. A body weight of ≥60 kg male and ≥50 kg female and a body mass index ranging from 18 to 30 kg/m2 (inclusive) at Screening.
- 5. Subjects and partners agree to use contraception throughout the study as detailed in the protocol.
- 6. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.
Exclusion Criteria:
- 1. Subjects with PR >240 ms, QRS ≥120 ms or corrected QT interval (QTc) by Fridericia's correction >450 ms for males and >470 ms for females on the Screening ECG, or any clinically significant ECG abnormality, in the opinion of the Investigator.
- 2. Subjects who have a history of cardiac disease or arrhythmias that can cause QTc prolongation.
- 3. Family history of long or short QT syndrome, hypokalaemia, syncope, or Torsades de Pointes.
- 4. Clinically significant (in the opinion of the Investigator) endocrine, thyroid, hepatic (including Gilbert's syndrome), respiratory, gastrointestinal (GI), renal (including estimated glomerular filtration rate <90 mL/min), cardiovascular disease, or history (within the last 2 years) of any significant psychiatric/psychotic illness disorder (including anxiety, depression and reactive depression).
- 5. Clinically relevant abnormal medical history, physical findings, or laboratory values at Screening or Day -1 that could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator.
- 6. Previously having received MT-8554.
- 7. Participation in more than 3 clinical studies involving administration of an IMP in the previous year, or any study within 12 weeks (or if relevant, 5 half-lives, whichever is longer) prior to the first dose.
- 8. Presence or history of severe adverse reaction or allergy to any medicinal product that is of clinical significance.
- 9. Subjects who have received any prescribed systemic or topical medication within 14 days (or if relevant, 5 half-lives; whichever is longer) prior to the first dose of IMP unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety. Subjects who have received slow release medicinal formulations considered to still be active within 14 days (or if relevant, 5 half-lives; whichever is longer) prior to the first dose administration will also be excluded unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety.
- 10. Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days (or, if relevant, five half-lives; whichever is longer) prior to the first dose of IMP unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety. Occasional use of paracetamol (acetaminophen) for mild analgesia is permitted.
- 11. Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days (or if relevant, 5 half lives; whichever is longer) prior to the first dose of IMP unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise safety.
- 12. Subjects with aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥1.5×upper limit of normal (ULN) or total bilirubin or creatine kinase above the reference range at Screening or Day -1.
- 13. Blood pressure (BP, supine) at Screening or Day -1 outside the range 90 to 140 mmHg (systolic) or 50 to 90 mmHg (diastolic); and pulse rate outside the range of 40 to 100 beats per minute (bpm), confirmed by repeat assessment. Evidence of postural hypotension defined as a decrease of >20 mmHg in systolic bp or >10 mmHg in diastolic bp between the supine and standing position, confirmed by repeat assessment.
- 14. Tympanic body temperature at Day -1 that is outside the local reference range, confirmed by repeat assessment.
- 15. Subjects who are pregnant (positive pregnancy test at Screening or Day -1) or lactating.
- 16. Presence or history of lactose intolerance.
- 17. Excessive consumption of food or drink containing caffeine, including coffee, tea, cola, energy drinks or chocolates (>5 cups of coffee or equivalent per day).
- 18. Presence or history of drug abuse (as defined by Diagnostic and Statistical Manual of Mental Disorders [DSM-V] criteria), or a positive urine test for drugs of abuse at Screening or Day 1.
- 19. Presence or history (in the last 2 years) of alcohol abuse, or intake of more than 28 units/224 g of alcohol weekly (for men) or 21 units/168 g of alcohol weekly (for women) or a positive breath test for alcohol at Screening or Day -1. One unit/8 g is equivalent to a half-pint (280 mL) of beer, 1 measure (25 mL) of spirits, or 1 glass (125 mL) of wine.
- 20. Subjects who use tobacco or nicotine-containing products (cigarettes, snuff, chewing tobacco, cigars, pipes, e-cigarettes or nicotine replacement products) within 3 months prior to dosing, or positive urine cotinine test at Screening or Day -1.
- 21. Test positive for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, or human immunodeficiency virus (HIV) 1 & HIV 2 antibodies at Screening.
- 22. Donate ≥1 units of blood (450 mL) in the 3 months prior to Screening, plasma in the 7 days prior to Screening, platelets in the 6 weeks prior to Screening, or intention to donate blood within 3 months after the last scheduled visit.
- 23. Consumption of food or drink containing Seville oranges, cranberry, liquorice or grapefruit from 7 days prior to Day -1.
24. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs; or which may jeopardise the subject in case or participation in the study. The Investigator should be guided by evidence of any of the following histories:
- Inflammatory bowel syndrome, gastritis, ulcers, GI or rectal bleeding
- Major GI surgery such as gastrectomy, gastroenterostomy, or bowel resection
- Clinical evidence of pancreatic injury or pancreatitis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose MT-8554 or placebo to match
Low dose MT-8554
|
Oral, 7 days
Oral, 7 days
|
Experimental: High dose MT-8554 or placebo to match
High dose MT-8554
|
Oral, 7 days
Oral, 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in QTcF with placebo adjustment
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with changes to QTcF from Baseline exceeding >30ms
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Proportion of subjects with changes to QTcF from Baseline exceeding >60ms
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Change in Heart Rate compared to baseline
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Change in PR Interval compared to baseline
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Change in QRS duration compared to baseline
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentration of MT-8554 with respect to time
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Plasma concentration of metabolite with respect to time
Time Frame: Days 1 & 7
|
Days 1 & 7
|
Number of participants with treatment related adverse events
Time Frame: Days 1 to 9
|
Days 1 to 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Head of Medical Science, Mitsubishi Tanabe Pharma America Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 23, 2018
Primary Completion (Actual)
October 19, 2018
Study Completion (Actual)
October 19, 2018
Study Registration Dates
First Submitted
February 28, 2018
First Submitted That Met QC Criteria
March 19, 2018
First Posted (Actual)
March 20, 2018
Study Record Updates
Last Update Posted (Actual)
May 15, 2023
Last Update Submitted That Met QC Criteria
May 12, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- MT-8554-E08
- 2017-004138-27 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenActive, not recruiting
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
-
AbbVieCompletedHealthy VolunteerUnited States
Clinical Trials on MT-8554 Low dose
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedPainful Diabetic Peripheral NeuropathyGermany, Hungary, Poland
-
Mitsubishi Tanabe Pharma America Inc.CompletedMenopause Hot FlashesUnited States
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma America Inc.CompletedVasomotor Symptoms (VMS)United States
-
Mitsubishi Tanabe Pharma America Inc.Completed
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedPainful Diabetic Peripheral NeuropathyJapan
-
Mitsubishi Tanabe Pharma America Inc.CompletedErythropoietic Protoporphyria (EPP)United States
-
Bausch Health Americas, Inc.Active, not recruitingUlcerative ColitisUnited States